Barclays PLC grew its holdings in Iradimed Corporation (NASDAQ:IRMD – Free Report) by 113.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,774 shares of the medical equipment provider’s stock after acquiring an additional 12,657 shares during the period. Barclays PLC’s holdings in Iradimed were worth $1,196,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of IRMD. Copeland Capital Management LLC increased its holdings in Iradimed by 0.3% in the 3rd quarter. Copeland Capital Management LLC now owns 422,425 shares of the medical equipment provider’s stock worth $21,244,000 after acquiring an additional 1,433 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Iradimed by 1.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 218,924 shares of the medical equipment provider’s stock valued at $9,620,000 after purchasing an additional 2,079 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Iradimed by 189.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 66,632 shares of the medical equipment provider’s stock valued at $3,351,000 after acquiring an additional 43,635 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Iradimed by 8.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 57,971 shares of the medical equipment provider’s stock worth $2,547,000 after purchasing an additional 4,363 shares in the last quarter. Finally, Oak Ridge Investments LLC bought a new position in shares of Iradimed during the third quarter worth $2,188,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.
Insider Activity at Iradimed
In related news, CFO John Glenn sold 2,500 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $54.18, for a total transaction of $135,450.00. Following the completion of the transaction, the chief financial officer now owns 4,383 shares in the company, valued at $237,470.94. The trade was a 36.32 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 37.10% of the stock is currently owned by insiders.
Iradimed Stock Down 0.1 %
Iradimed Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, November 25th. Shareholders of record on Friday, November 15th were paid a dividend of $0.15 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $0.60 annualized dividend and a yield of 1.06%. Iradimed’s payout ratio is currently 41.10%.
About Iradimed
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.
See Also
- Five stocks we like better than Iradimed
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- Insider Buying Explained: What Investors Need to Know
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- 3 Healthcare Dividend Stocks to Buy
- Delta Can Fly to New Highs in 2025; Here’s Why
Want to see what other hedge funds are holding IRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iradimed Corporation (NASDAQ:IRMD – Free Report).
Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.